Grant: CIHR Fellowship
Direct Payment
$50,000.00
Investigating a protective role for miR-122 in the life cycle of Hepatitis C virus
EF 2010-11
Résumé
Hepatitis C virus (HCV) infection is a rapidly increasing global health problem. Approximately 170 million people are infected worldwide including over 250 000 Canadians. HCV infection is characterized by chronic liver inflammation which often progresses to cirrhosis and hepatocellular carcinoma. Currently, there is no vaccine available and the treatment is non-specific, toxic, expensive, and relatively ineffective. Thus, there is a pressing need for novel anti-HCV treatments.
To establish an infection, HCV co-opts many different factors in our cells. In healthy cells, small RNA molecules restrict how much our genes are expressed. HCV commandeers a liver-specific small RNA and uses it to amplify the viral genome. The focus of the proposed research is to investigate how this small RNA increases the amount of the HCV genome and to identify associated factors that determine the destiny of viral genomes in infected cells.
Previous results have shown that the small RNA does not help the virus make its proteins and does not participate in copying the virus. I have recently provided evidence that the small RNA interacts with the very end of the HCV genome, suggesting the small RNA might protect the end of the virus from being degraded or from being recognized by our immune system. To investigate this, I am using a technique called RNA interference to dramatically reduce the amount of specific factors and then examining the effect on HCV accumulation. In this way, I can determine which factors are important for mediating HCV RNA abundance.
At present, most therapeutic approaches specifically target the virus. However, HCV is able to mutate to escape the effect of these drugs. Recently, a drug used to sequester this small RNA in HCV-infected chimpanzees was demonstrated to have long-lasting suppression of HCV, with no evidence of viral resistance or adverse side effects. These results suggest that this small host RNA molecule is a promising antiviral target.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
214215
Name
Sagan Selena M
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Investigating a protective role for miR-122 in the life cycle of Hepatitis C virus
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
5' End; Antisense Locked Nucleic Acid (Lna); Hepatitis C Virus; Microrna (Mirna); Mir-122; Rna Immunoprecipitation; Rna Secondary Structure; Short-Interfering Rna (Sirna); Sirna Knockdown
Abstract
Hepatitis C virus (HCV) infection is a rapidly increasing global health problem. Approximately 170 million people are infected worldwide including over 250 000 Canadians. HCV infection is characterized by chronic liver inflammation which often progresses to cirrhosis and hepatocellular carcinoma. Currently, there is no vaccine available and the treatment is non-specific, toxic, expensive, and relatively ineffective. Thus, there is a pressing need for novel anti-HCV treatments.
To establish an infection, HCV co-opts many different factors in our cells. In healthy cells, small RNA molecules restrict how much our genes are expressed. HCV commandeers a liver-specific small RNA and uses it to amplify the viral genome. The focus of the proposed research is to investigate how this small RNA increases the amount of the HCV genome and to identify associated factors that determine the destiny of viral genomes in infected cells.
Previous results have shown that the small RNA does not help the virus make its proteins and does not participate in copying the virus. I have recently provided evidence that the small RNA interacts with the very end of the HCV genome, suggesting the small RNA might protect the end of the virus from being degraded or from being recognized by our immune system. To investigate this, I am using a technique called RNA interference to dramatically reduce the amount of specific factors and then examining the effect on HCV accumulation. In this way, I can determine which factors are important for mediating HCV RNA abundance.
At present, most therapeutic approaches specifically target the virus. However, HCV is able to mutate to escape the effect of these drugs. Recently, a drug used to sequester this small RNA in HCV-infected chimpanzees was demonstrated to have long-lasting suppression of HCV, with no evidence of viral resistance or adverse side effects. These results suggest that this small host RNA molecule is a promising antiviral target.
Competitiondate
201010
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sagan, Selena M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $50,000~ $0~